Viking Therapeutics, Inc.(VKTX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

VKTX Viking Therapeutics, Inc.

已收盘 11-21 16:00:00 EST

51.63

+0.10

+0.19%

盘后52.00

+0.37+0.72%

19:58 EST

最高54.28	最低50.53	成交量328.90万
今开51.30	昨收51.53	日振幅7.28%
总市值57.53亿	流通市值54.45亿	总股本1.11亿
成交额1.72亿	换手率3.12%	流通股本1.05亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"VKTX","market":"US","secType":"STK","nameCN":"Viking Therapeutics, Inc.","latestPrice":51.63,"timestamp":1732222800000,"preClose":51.53,"halted":0,"volume":3288990,"hourTrading":{"tag":"盘后","latestPrice":52,"preClose":51.63,"latestTime":"19:58 EST","volume":68311,"amount":3532794.8024,"timestamp":1732237129837},"delay":0,"floatShares":105459203,"shares":111436384,"eps":-0.933775,"marketStatus":"已收盘","marketStatusCode":5,"change":0.1,"latestTime":"11-21 16:00:00 EST","open":51.3,"high":54.2799,"low":50.5265,"amount":172095665.01624,"amplitude":0.072839,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.933775,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1732266000000},"adr":0,"listingDate":1430280000000,"adjPreClose":51.53,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":51.2,"preClose":51.53,"latestTime":"09:29 EST","volume":31557,"amount":1638604.16754,"timestamp":1732199382792},"postHourTrading":{"tag":"盘后","latestPrice":52,"preClose":51.63,"latestTime":"19:58 EST","volume":68311,"amount":3532794.8024,"timestamp":1732237129837},"volumeRatio":0.632892,"optionData":{"bulkOrders":[{"symbol":"VKTX","call":true,"expireDate":1737090000000,"strike":"57.5","timestamp":1732202914768,"price":5.050000190734863,"volume":1050,"amount":530250,"type":"+"}]},"impliedVol":0.839,"impliedVolPercentile":0.2024},"requestUrl":"/m/hq/s/VKTX/wiki","defaultTab":"wiki","newsList":[{"id":"2484001146","title":"BUZZ--美国股票走势-Williams-Sonoma, Inspire Medical, Lemonade Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2484001146","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484001146?lang=zh_cn&edition=full","pubTime":"2024-11-20 23:57","pubTimestamp":1732118258,"startTime":"0","endTime":"0","summary":".N美国东部时间10:30，道琼斯工业平均指数.DJI下跌0.28%，报43,145.73点。标普500指数.SPX下跌0.78%，报5870.84点；纳斯达克综合指数.IXIC下跌1.16%，报18769.66点。标准普尔 500 指数.PG.INX涨幅前三名是： ** Keysight Technologies Inc KEYS.N，上涨 5.9. nL4N3MR0SH  ** 金山云控股有限公司KC.O:BUZZ - 因第三季度亏损小于预期而上涨 nL8N3MR11B  ** Silvercorp Metals Inc SVM.N:BUZZ - 在公布可转换债务交易后下跌 nL6N3MR0HA  ** Tapestry Inc TPR.N： ** Capri Holdings Ltd CPRI.N:BUZZ - 巴克莱恢复对Tapestry和Capri的覆盖。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nL4T3MR19F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QDEL","BK4516","DAL","BK4555","BK4554","BK4539","CTVA","INSP","IE00B1BXHZ80.USD","LU0980610538.SGD","CMCSA","LU0075056555.USD","MNPR","BK4507","SPAI","LMND","LU0289961442.SGD","CMI","NEM","LU0094547139.USD","LU1430597077.USD","LU0950375773.USD","WIX","TJX","F","VKTX","LU1267930490.SGD","TGT","FLEX","GDRX","POWL","BK4195","SAGE","TPR","LU0788108826.HKD","WSM","LU0310800965.SGD","SM","BGC","OMCL","LU1280957306.USD","DTM","CPRI","MBIN"],"gpt_icon":1},{"id":"2484112793","title":"BUZZ--美国股票走势-康卡斯特、Wix.com、Flex","url":"https://stock-news.laohu8.com/highlight/detail?id=2484112793","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484112793?lang=zh_cn&edition=full","pubTime":"2024-11-20 22:31","pubTimestamp":1732113071,"startTime":"0","endTime":"0","summary":"** Wix.com Ltd   : BUZZ - 因上调财年营收和预订预期而跳涨   ** GoodRx Holdings Inc   : BUZZ - Leerink 表示，该公司是价值被低估最严重的股票之一，    。** 达美航空  : BUZZ - 预测 2025 年收入将实现中等个位数增长，随后上涨。** 金山云控股有限公司  : BUZZ - 因第三季度亏损小于预期而上涨   ** Silvercorp Metals Inc   : BUZZ - 在公布可转换债务交易后下跌","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4008","LU0124676726.USD","COIN","FLEX","TGT","LU0456854461.SGD","LU0630314457.HKD","LU0057025933.USD","BK4114","LU0289961442.SGD","QDEL","BGC","LU2098885051.SGD","WIX","VKTX","LU1223083913.SGD","DAL","BK4100","BK4195","NEM","LU0154245756.USD","SPAI","GDRX","SAGE","LU1150488218.USD","BK4551","BK4516","LU0788108826.HKD","BK4112","RIOT","SM","LU0823411888.USD","BK4198","MBIN","BK4596","LU0320765489.SGD","LU1861559042.SGD","LU0612318385.USD","LU0648001328.SGD","BK4567","CMI","MARA","MNPR","LU1280957306.USD","BK4554","CMCSA","CTVA"],"gpt_icon":1},{"id":"2484619797","title":"BUZZ--美国股票走势-目标、加密股票、黄金矿工","url":"https://stock-news.laohu8.com/highlight/detail?id=2484619797","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484619797?lang=zh_cn&edition=full","pubTime":"2024-11-20 20:15","pubTimestamp":1732104930,"startTime":"0","endTime":"0","summary":"nL4N3MR0O5 (为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nL4S3MR0UG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNVD.UK","MARA","EVS.SI","LU1623119135.USD","NVDU","LU1868837300.USD","NVDS.UK","NVD3.UK","NVDY","2NVD.UK","LU0528227936.USD","NVDS","LU0368265764.SGD","MBIN","SGXZ23171101.USD","VKTX","BK4114","LU0048584097.USD","LU1814569148.SGD","LU0234572021.USD","NVD","NEM","NVD2.UK","LU0097036916.USD","LU1989764664.SGD","BK4579","LU0289961442.SGD","LU1023059493.AUD","RIOT","NVDX","PIPR","3NVD.UK","NIO.SI","LU1935043023.USD","BGC","BK4548","LU0823414478.USD","NVDD","NVDA","TGT","LU1223082196.USD","LU1316542783.SGD","COIN","BK4555"],"gpt_icon":1},{"id":"2484013193","title":"BUZZ-维京公司因肝病药物的详细中期数据而获益","url":"https://stock-news.laohu8.com/highlight/detail?id=2484013193","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484013193?lang=zh_cn&edition=full","pubTime":"2024-11-20 18:42","pubTimestamp":1732099360,"startTime":"0","endTime":"0","summary":"    11月20日 - ** Viking Therapeutics   股价在收盘前上涨约4%至53.52美元 ** 药物开发商在一次医学会议上公布了试验性肝病药物VK2809中期试验的最终结果 ** 详细数据显示，接受该药物治疗的患者肝组织纤维化或瘢痕的改善率为44%至57%，而安慰剂的改善率为34%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","VKTX","BK4585"],"gpt_icon":0},{"id":"1106223865","title":"政策压力下率先反弹，“减肥药新贵”Viking能否抗衡“诺礼双雄”？","url":"https://stock-news.laohu8.com/highlight/detail?id=1106223865","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106223865?lang=zh_cn&edition=full","pubTime":"2024-11-20 18:33","pubTimestamp":1732098801,"startTime":"0","endTime":"0","summary":"不过从实际情况来看，肥胖人群对减肥药物的需求持续高企，而“减肥药新贵” Viking的新型口服减肥药VK2809后来居上，甚至有力压老牌减肥药物巨头“诺礼双雄”的势头。此前，Viking还公布了VK2735注射版的最新数据。考虑到规模及品牌效应，目前主导肥胖药物领域的仍然是诺和诺德和礼来两大巨头，但“减肥药新贵”Viking的异军突起，或许将让他们未来面临严峻的竞争。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO","VKTX","LLY"],"gpt_icon":0},{"id":"2484903076","title":"Viking Therapeutics, Inc.盘中异动 快速上涨5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484903076","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484903076?lang=zh_cn&edition=full","pubTime":"2024-11-20 04:57","pubTimestamp":1732049823,"startTime":"0","endTime":"0","summary":"北京时间2024年11月20日04时57分，Viking Therapeutics, Inc.股票出现异动，股价大幅上涨5.03%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.68%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120045703a246975d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120045703a246975d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4588","VKTX","LENZ","BK4139"],"gpt_icon":0},{"id":"2483304637","title":"Viking Therapeutics, Inc.盘中异动 快速跳水5.11%报50.83美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2483304637","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483304637?lang=zh_cn&edition=full","pubTime":"2024-11-16 00:46","pubTimestamp":1731689195,"startTime":"0","endTime":"0","summary":"北京时间2024年11月16日00时46分，Viking Therapeutics, Inc.股票出现异动，股价急速下挫5.11%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为3.81%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111600463598e4300e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111600463598e4300e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","LENZ","VKTX","BK4139","BK4588"],"gpt_icon":0},{"id":"2483839105","title":"Viking Therapeutics, Inc.盘中异动 临近午盘大幅下跌5.00%报57.57美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2483839105","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483839105?lang=zh_cn&edition=full","pubTime":"2024-11-14 00:48","pubTimestamp":1731516502,"startTime":"0","endTime":"0","summary":"北京时间2024年11月14日00时48分，Viking Therapeutics, Inc.股票出现异动，股价大幅下跌5.00%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.11%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114004822a234a2cb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114004822a234a2cb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","LENZ","VKTX","BK4139","BK4588"],"gpt_icon":0},{"id":"2482087805","title":"Viking Therapeutics, Inc.盘中异动 急速下跌5.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2482087805","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482087805?lang=zh_cn&edition=full","pubTime":"2024-11-12 23:36","pubTimestamp":1731425772,"startTime":"0","endTime":"0","summary":"北京时间2024年11月12日23时36分，Viking Therapeutics, Inc.股票出现异动，股价快速下挫5.30%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.27%。其相关个股中，Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Cero Therapeutics Holdings, Inc.、Geovax Labs Inc C/Wts 29/09/2025涨幅较大，Cero Therapeutics Holdings, Inc.、Geovax Labs, Inc.、Elevai Labs, Inc.较为活跃，换手率分别为305.14%、170.12%、144.98%，振幅较大的相关个股有Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Geovax Labs Inc C/Wts 29/09/2025，振幅分别为84.88%、65.13%、61.82%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111223361298e421d0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111223361298e421d0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","BK4588","BK4585","VKTX"],"gpt_icon":0},{"id":"2482758243","title":"Viking Therapeutics, Inc.盘中异动 快速下跌5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2482758243","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482758243?lang=zh_cn&edition=full","pubTime":"2024-11-12 01:13","pubTimestamp":1731345236,"startTime":"0","endTime":"0","summary":"北京时间2024年11月12日01时13分，Viking Therapeutics, Inc.股票出现异动，股价快速下挫5.03%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.19%。其相关个股中，Cero Therapeutics Holdings, Inc.、Aligos Therapeutics, Inc.、Cero Therapeutics Holdings Inc C/Wts 13/02/2029 涨幅较大，Cero Therapeutics Holdings, Inc.、Revelation Biosciences, Inc.、Elevai Labs, Inc.较为活跃，换手率分别为689.25%、493.65%、205.63%，振幅较大的相关个股有Cero Therapeutics Holdings, Inc.、Aligos Therapeutics, Inc.、Lakeshore Biopharma Co., Ltd，振幅分别为123.43%、72.42%、61.39%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112011356a22d3457&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112011356a22d3457&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VKTX","LENZ","BK4588","BK4139","BK4585"],"gpt_icon":0},{"id":"1141989672","title":"异动解读 | 新兴生物制药公司Viking Therapeutics新药VK2735攻陷\"胖子市场\"","url":"https://stock-news.laohu8.com/highlight/detail?id=1141989672","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141989672?lang=zh_cn&edition=full","pubTime":"2024-11-05 22:56","pubTimestamp":1730818608,"startTime":"0","endTime":"0","summary":"在肥胖症治疗市场,诺和诺德和礼来公司的减肥药物一直占据主导地位。但周一公布的一项新数据或将改变这一格局。新兴生物制药公司Viking Therapeutics公布了其新型减肥药VK2735的临床试验数据。根据Viking Therapeutics公布的数据,VK2735口服剂型在28天试验中能使受试者平均减重8.2%。相比之下,口服VK2735或将为不愿注射的患者提供新的选择。另一方面,VK2735注射剂可实现每月一次给药,而Wegovy和Zepbound需要每周注射一次。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["VKTX"],"gpt_icon":0},{"id":"2481851436","title":"Viking Therapeutics, Inc.盘中异动 早盘股价大涨5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2481851436","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481851436?lang=zh_cn&edition=full","pubTime":"2024-11-05 22:54","pubTimestamp":1730818445,"startTime":"0","endTime":"0","summary":"北京时间2024年11月05日22时54分，Viking Therapeutics, Inc.股票出现异动，股价大幅拉升5.02%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.56%。其相关个股中，Bionomics Ltd Ads Each Rep 180 Ord Shs、Zyversa Therapeutics, Inc.、Nutriband Inc C/Wts 涨幅较大，Zyversa Therapeutics, Inc.、Bionomics Ltd Ads Each Rep 180 Ord Shs、Elevai Labs, Inc.较为活跃，换手率分别为4278.35%、1404.26%、489.80%，振幅较大的相关个股有Bionomics Ltd Ads Each Rep 180 Ord Shs、Zyversa Therapeutics, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029，振幅分别为67.30%、42.31%、19.51%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241105225405aba2477f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241105225405aba2477f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","LENZ","VKTX","BK4588","BK4139"],"gpt_icon":1},{"id":"1165551400","title":"Viking Therapeutics减肥药异军突起，“诺礼双雄”面临挑战","url":"https://stock-news.laohu8.com/highlight/detail?id=1165551400","media":"老虎资讯综合","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165551400?lang=zh_cn&edition=full","pubTime":"2024-11-05 11:38","pubTimestamp":1730777920,"startTime":"0","endTime":"0","summary":"Viking Therapeutics周一早些时候公布的减肥药VK2735的数据表明，目前主导肥胖药物领域的诺和诺德和礼来未来可能面临严峻竞争。VK2735目前正在开发注射和片剂两种剂型，与礼来的Zepbound关系最为密切，因为两者都是GLP-1/GIP双重激动剂。同一项研究显示，在52周内体重减轻了15.7%。在6月的Seeking Alpha投资峰会上，Cantor Fitzgerald董事总经理Louise Chen表示，与竞争对手相比，orforglipron在开发方面处于领先地位。这家丹麦制药公司此前曾表示，预计CagriSema和amycetin的减肥效果将优于Wegovy。","market":"us","thumbnail":"https://static.tigerbbs.com/32434a321ba3d88daee05916d354f003","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/32434a321ba3d88daee05916d354f003"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b370e26f2720fe107e8c7591e53ab381","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Viking Therapeutics减肥药异军突起，“诺礼双雄”面临挑战","news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VKTX"],"gpt_icon":1},{"id":"2481921590","title":"Viking Therapeutics减肥药异军突起 “诺礼双雄”面临挑战","url":"https://stock-news.laohu8.com/highlight/detail?id=2481921590","media":"智通财经网","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481921590?lang=zh_cn&edition=full","pubTime":"2024-11-05 10:39","pubTimestamp":1730774362,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，Viking Therapeutics周一早些时候公布的减肥药VK2735的数据表明，目前主导肥胖药物领域的诺和诺德和礼来未来可能面临严峻竞争。VK2735目前正在开发注射和片剂两种剂型，与礼来的Zepbound关系最为密切，因为两者都是GLP-1/GIP双重激动剂。周一，Viking还公布了VK2735注射版的最新数据。在6月的Seeking Alpha投资峰会上，Cantor Fitzgerald董事总经理Louise Chen表示，与竞争对手相比，orforglipron在开发方面处于领先地位。这家丹麦制药公司此前曾表示，预计CagriSema和amycetin的减肥效果将优于Wegovy。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241105104505aba00b48&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241105104505aba00b48&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0417517546.SGD","LU0094547139.USD","LU0385154629.USD","LU0708995401.HKD","VKTX","LU0943347566.SGD","LU0289739699.SGD","LU0061475181.USD","LU0203202063.USD","LU0820561818.USD","LU0106261372.USD","LU0882574055.USD","LU0672654240.SGD","LU0096364046.USD","IE0004445239.USD","IE00BJLML261.HKD","IE00BJT1NW94.SGD","LU0006306889.USD","LLY","LU0354030511.USD","IE00BJJMRZ35.SGD","LU1035775433.USD","LU0203201768.USD","LU0354030438.USD","LU1093756168.USD","LU0820561909.HKD","LU0320765059.SGD","BK4139","LU0097036916.USD","LU0114720955.EUR","IE00BK4W5M84.HKD","LU1061106388.HKD","BK4585","BK4007","LU0058720904.USD","LU0109391861.USD","IE0002141913.USD","IE00B1BXHZ80.USD","LU0122379950.USD","GB00BDT5M118.USD","LU1069344957.HKD","LU0238689110.USD","BK4533","IE00BFTCPJ56.SGD","LU0456855351.SGD","LU1057294990.SGD","NVO","BK4588","LU1023059063.AUD","BK4581","LENZ","IE0009355771.USD"],"gpt_icon":1},{"id":"1136575890","title":"异动解读 | Viking Therapeutics口服减肥药初见成效 股价大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=1136575890","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136575890?lang=zh_cn&edition=full","pubTime":"2024-11-05 01:56","pubTimestamp":1730742993,"startTime":"0","endTime":"0","summary":"生物技术公司Viking Therapeutics周一盘前股价大涨24%,此前该公司公布了令人鼓舞的早期研究结果:其实验性口服减肥药物VK2735在高剂量下可使患者在28天内平均减轻8.2%体重。分析师认为,如果数据在后续大规模试验中得到验证,VK2735将在庞大且不断增长的减肥药物市场上占据有利地位。Viking公司计划在2024年底之前开始VK2735的二期临床试验。投资者认为,作为首批实现简单口服的减肥药之一,Viking的药物有望在未来较长一段时间内保持独特优势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b370e26f2720fe107e8c7591e53ab381","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["VKTX"],"gpt_icon":0},{"id":"2481323005","title":"BUZZ-维京公司因生产问题而下跌，口服肥胖症药物数据蒙上阴影","url":"https://stock-news.laohu8.com/highlight/detail?id=2481323005","media":"Reuters","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481323005?lang=zh_cn&edition=full","pubTime":"2024-11-05 01:53","pubTimestamp":1730742786,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 )) (更新)    11月4日 - ** Viking Therapeutics   股价下跌7.92%至67.15美元，扭转了 盘前涨势** 该公司在《肥胖周》（ObesityWeek）会议上公布了其试验性口服肥胖症药物VK2735的 (link)。** 在一项早期试验中，服用 100 毫克剂量药物的患者在 28 天内体重减轻了 8.2** 分析师说，投资者可能会担心该公司生产该产品的能力**Viking 公司的数据看起来很有竞争力，但还需要更长时间和更大规模的研究来验证。** 股价在过去一年里几乎翻了两番","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","VKTX","BK4139","BK4588"],"gpt_icon":0},{"id":"2481534821","title":"更新版 2-更新 2-阿斯利康称实验性肥胖药在早期试验中是安全的","url":"https://stock-news.laohu8.com/highlight/detail?id=2481534821","media":"路透中文","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481534821?lang=zh_cn&edition=full","pubTime":"2024-11-04 23:39","pubTimestamp":1730734740,"startTime":"0","endTime":"0","summary":"更新版 2-更新 2-阿斯利康称实验性肥胖药在早期试验中是安全的更新第 3 段中的份额，在第 12-15 段中增加有关其他肥胖症药物数据的细节Maggie Fick. 路透伦敦11月4日 - 阿斯利康AZN.L周一称，其一年前以20亿美元从中国爱可吉公司获得许可的实验性减肥药在早期试验中是安全和可耐受的，副作用与GLP-1类药物一致。数据公布后，阿斯利康的股价最高上涨了2.9%，随后跌幅收窄。阿斯利康公司还公布了其他主要肥胖试验药物的一期试验数据，这些药物都是注射剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241104:nL4S3MB18F:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","LU0471298694.HKD","IE00B19Z3B42.SGD","IE00BK4W5L77.USD","LU0122379950.USD","BK4592","LU0882574055.USD","LU0198837287.USD","LU0985481810.HKD","LU0820561909.HKD","LU0234572021.USD","PFE","LU0320765059.SGD","IE00B1BXHZ80.USD","LU1023059063.AUD","BK4568","LU1064131342.USD","LLY","LU0094547139.USD","LU0203202063.USD","LU1069344957.HKD","SGXZ57979304.SGD","LU0321505439.SGD","BK4588","LU0225771236.USD","LU1894683264.USD","BK4139","LU0321505868.SGD","BK4516","LU0820561818.USD","SG9999001176.SGD","SG9999002224.SGD","LU0708995401.HKD","LU0672654240.SGD","LU0096364046.USD","LU0385154629.USD","LU0823416689.USD","BK4007","SG9999013999.USD","LU0354030511.USD","LU1066053197.SGD","LU0466842654.USD","LU0640476718.USD","BK4550","IE0002270589.USD","BK4534","LU0943347566.SGD","VKTX","BK4581","IE00B4R5TH58.HKD"],"gpt_icon":1},{"id":"2480058149","title":"Viking Therapeutics, Inc.盘中异动 股价大涨6.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2480058149","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480058149?lang=zh_cn&edition=full","pubTime":"2024-11-04 22:31","pubTimestamp":1730730665,"startTime":"0","endTime":"0","summary":"北京时间2024年11月04日22时31分，Viking Therapeutics, Inc.股票出现异动，股价大幅拉升6.64%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.14%。其相关个股中，Nls Pharmaceutics Ltd.、Disc Medicine, Inc.、Neurogene Inc.涨幅较大，Nls Pharmaceutics Ltd.、Elevai Labs, Inc.、Gri Bio, Inc.较为活跃，换手率分别为228.49%、122.56%、39.41%，振幅较大的相关个股有BioCryst制药、Gri Bio, Inc.、Oncolytics Biotech Inc.，振幅分别为6.17%、4.55%、4.24%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110422310595bdc985&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110422310595bdc985&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4585","BK4588","LENZ","VKTX"],"gpt_icon":1},{"id":"2480589367","title":"iking Therapeutics(VKTX)：旗下VK2735减肥药研究成效显著","url":"https://stock-news.laohu8.com/highlight/detail?id=2480589367","media":"金吾财讯","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480589367?lang=zh_cn&edition=full","pubTime":"2024-11-04 22:20","pubTimestamp":1730730047,"startTime":"0","endTime":"0","summary":"金吾财讯 | iking Therapeutics 宣布，其试验性药物VK2735在较高剂量下相比早期配方能更有效地减轻患者体重，这为其与诺和诺德和礼来的重磅药物竞争奠定了坚实基础。在一项早期研究中，服用100毫克VK2735的受试者在28天内平均减重8.2%，相比之下，服用安慰剂的患者减重6.8%。投资者对Viking公司打入减肥药市场的潜力表示看好，今年其股价已上涨三倍。Viking的药物以易于服用的药丸形式出现，有望成为目前市场上占主导地位的注射剂的替代品，产生重大影响。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210625/OTU2NGE4NGJmZTIzZDc2N2YxYmJkM2MyMjUzODQzOTQ1NzY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/OTU2NGE4NGJmZTIzZDc2N2YxYmJkM2MyMjUzODQzOTQ1NzY=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"281608","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4585","NVO","BK4588","LLY","LENZ","VKTX"],"gpt_icon":0},{"id":"2480440304","title":"早期口服肥胖症药物数据超出预期，Viking Therapeutics 公司业绩飙升","url":"https://stock-news.laohu8.com/highlight/detail?id=2480440304","media":"Reuters","labels":["Business Data"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480440304?lang=zh_cn&edition=full","pubTime":"2024-11-04 20:22","pubTimestamp":1730722936,"startTime":"0","endTime":"0","summary":"    路透11月4日 - Viking Therapeutics   周一盘前股价大涨25%，因为该公司实验性口服肥胖症药物的早期数据显示其减肥效果和安全性超出了华尔街的预期。今年到目前为止，Viking公司的股价几乎翻了两番，因为这家药物开发商正在争夺潜在的价值1500亿美元的肥胖症治疗市场，该市场由礼来公司  的Zepbound和诺和诺德公司  的Wegovy等减肥药主导。礼来公司正在晚期试验一种口服减肥药，该公司股价盘前下跌2.3%，至800.15美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b370e26f2720fe107e8c7591e53ab381","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRZ35.SGD","LU0170899867.USD","IE00BJLML261.HKD","LU0225771236.USD","LU0354030511.USD","IE0009355771.USD","IE00B2B36J28.USD","LU1061106388.HKD","LU0820561818.USD","IE00B19Z3581.USD","LU0079474960.USD","VKTX","BK4533","IE00B19Z3B42.SGD","BK4581","LU0094547139.USD","LU0203201768.USD","IE000M9KFDE8.USD","BK4139","IE00BLSP4239.USD","LU0097036916.USD","LU0198837287.USD","LU0122379950.USD","LU0289739699.SGD","LU1894683348.USD","LU1066053197.SGD","BK4585","IE00BLSP4452.SGD","LENZ","LU0708995401.HKD","LU0234572021.USD","BK4534","LU0006306889.USD","LU0058720904.USD","LU1883839398.USD","IE0004445239.USD","LU0321505439.SGD","BK4568","LLY","LU0096364046.USD","LU0114720955.EUR","IE00BK4W5M84.HKD","LU0471298777.SGD","BK4007","LU0823416689.USD","SG9999002224.SGD","LU0689472784.USD","BK4588","LU1069344957.HKD","RKLB"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.vikingtherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0641},{"period":"1month","weight":-0.1991},{"period":"3month","weight":-0.1992},{"period":"6month","weight":-0.1788},{"period":"1year","weight":3.5401},{"period":"ytd","weight":1.7689}],"compareEarnings":[{"period":"1week","weight":-0.0112},{"period":"1month","weight":0.0118},{"period":"3month","weight":0.0616},{"period":"6month","weight":0.1153},{"period":"1year","weight":0.3028},{"period":"ytd","weight":0.2423}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Viking Therapeutics, Inc.于2012年9月24号在特拉华州成立。该公司是一个临床阶段的生物制药公司，致力于开发新的，第一类或最好的新陈代谢和内分泌失调类疗法。该公司拥有全球独家权利基于许可的配体小分子组合在五个候选药物在临床试验或临床前研究。公司的主导临床程序是VK0612，它是进入2b期临床试验为2型全球最大的健康挑战之一的治疗糖尿病疾病口服药物，它在同药物中排列第一。公司的第二临床程序vk5211，可把口服的候选药物送入第二阶段临床试验治疗一种复杂的疾病特点的不受控制的肌肉质量下降癌症恶病。VK5211是一种非甾体选择性雄激素受体调节剂，或SARM。","yearOnYearQuotes":[{"month":1,"riseRate":0.555556,"avgChangeRate":0.031825},{"month":2,"riseRate":0.555556,"avgChangeRate":0.264573},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.020024},{"month":4,"riseRate":0.444444,"avgChangeRate":-0.000523},{"month":5,"riseRate":0.3,"avgChangeRate":0.094367},{"month":6,"riseRate":0.4,"avgChangeRate":-0.023196},{"month":7,"riseRate":0.5,"avgChangeRate":-0.005074},{"month":8,"riseRate":0.5,"avgChangeRate":0.030421},{"month":9,"riseRate":0.3,"avgChangeRate":0.062199},{"month":10,"riseRate":0.3,"avgChangeRate":0.012685},{"month":11,"riseRate":0.5,"avgChangeRate":-0.018614},{"month":12,"riseRate":0.666667,"avgChangeRate":0.206888}],"exchange":"NASDAQ","name":"Viking Therapeutics, Inc.","nameEN":"Viking Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Viking Therapeutics, Inc.(VKTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Viking Therapeutics, Inc.(VKTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Viking Therapeutics, Inc.,VKTX,Viking Therapeutics, Inc.股票,Viking Therapeutics, Inc.股票老虎,Viking Therapeutics, Inc.股票老虎国际,Viking Therapeutics, Inc.行情,Viking Therapeutics, Inc.股票行情,Viking Therapeutics, Inc.股价,Viking Therapeutics, Inc.股市,Viking Therapeutics, Inc.股票价格,Viking Therapeutics, Inc.股票交易,Viking Therapeutics, Inc.股票购买,Viking Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Viking Therapeutics, Inc.(VKTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Viking Therapeutics, Inc.(VKTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}